Key Highlights
- EBS reported third-quarter 2026 Revenue of $110.0 million, down 52% from $231.1 million.
- Net loss was $32.7 million, or $0.64 per diluted share, against Net Income of $51.2 million a year earlier.
- Adjusted EBITDA was a loss of $4.6 million, compared with a profit of $92.6 million.
- Full-year 2026 revenue guidance was cut to $600 million to $645 million from $645 million to $675 million.
- Gross Debt stood at $514 million and net Leverage at 2.4x trailing 12-month adjusted EBITDA, according to management.
Revenue Halves as Smallpox and Naloxone Sales Fall
Emergent BioSolutions (NYSE:EBS) reported results for the third quarter ended Sep 30, 2026 on Nov 2, 2026. Total revenue was $110.0 million, down 52% from $231.1 million, and in line with the company's own guidance. The net loss was $32.7 million, or $0.64 per diluted share, versus net income of $51.2 million, or $0.91 per share.
The company sells medical countermeasures for biological threats and the NARCAN and KLOXXADO naloxone nasal sprays. Naloxone revenue fell 42% to $43.5 million on weaker over-the-counter NARCAN pricing and Volume in U.S. public interest channels, partly offset by Canadian sales. Smallpox countermeasures dropped 68% to $26.7 million on the timing of government orders.
Anthrax countermeasures rose to $25.1 million from $1.4 million on timing of U.S. government purchases. Other products fell 87% to $7.6 million.
Gross Margin Compresses to 14% and Adjusted EBITDA Turns Negative
Gross margin was 14%, versus 54% a year earlier, and adjusted gross margin was 28%, versus 62%. Adjusted EBITDA was a loss of $4.6 million, a negative 4% margin, compared with $92.6 million and a 40% margin. Adjusted net loss was $18.7 million, or $0.36 per share.
Selling, general and administrative expense rose 20% to $46.5 million, reflecting severance tied to an August 2026 restructuring and a one-time litigation insurance reimbursement in the prior-year quarter. Research and Development fell 30% to $9.4 million. Management said the restructuring should deliver about $40 million of annualized savings, with the first impact in the fourth quarter.
For the nine months, revenue was $500.4 million, down from $594.2 million, and the net loss was $206.1 million, including a $191.3 million non-cash Impairment recorded in the second quarter.
Revenue Guidance Falls to $600 Million to $645 Million, Margin Range Rises
The company now expects 2026 revenue of $600 million to $645 million, down from $645 million to $675 million set on Aug 5, 2026. Adjusted EBITDA guidance moved to $110 million to $140 million from $130 million to $150 million.
Management said medical countermeasure revenue should decline from last year because some international and U.S. government deliveries may slip beyond the fourth quarter, and commercial revenue is tracking toward the low end of an expected 20% to 25% decline. Adjusted gross margin guidance rose to 45% to 47% from 42% to 44%, helped by Manufacturing improvements, product mix and stabilizing U.S. NARCAN pricing.
Cash Flow, Debt Paydown and a CFO Transition Frame the Year-End Push
Operating Cash Flow was $122.4 million for the nine months, versus $92.9 million. Cash was $175.7 million with $226 million of total liquidity. The company repurchased $75 million of unsecured notes for $68 million, leaving gross debt at $514 million and net debt at $339 million, and bought back 2.0 million shares for $18.1 million, with $37.3 million of authorization left.
The chief financial officer will retire effective Dec 31, 2026. Next to watch are the timing of remaining government and international deliveries in the fourth quarter and early 2027, which management said will set where full-year revenue lands within its range.






Please wait processing your request...